Core Insights - The company, CloudTop New Horizon, has established a solid foundation over the past eight years through license-in strategies and aims to become a leading global biopharmaceutical company by 2030 with a revenue target of over 15 billion RMB and more than 20 commercialized products [1][2][10] Group 1: Strategic Development - The 2030 development strategy focuses on a dual approach of business development (BD) cooperation and independent research and development, targeting a revenue of over 15 billion RMB and over 20 commercialized products by 2030 [1][2][10] - The company plans to introduce 3-5 late-stage blockbuster products annually over the next five years, enhancing its product pipeline [3][10] - The strategic partnerships with Haisen Biopharmaceuticals will provide commercialization services for six approved products, generating service fees based on quarterly net sales [3][4] Group 2: Product Pipeline and Market Focus - The company will focus on key therapeutic areas such as nephrology, autoimmune diseases, critical care, cardiovascular, and ophthalmology, aiming to create a high-value product portfolio by 2030 [2][10] - The revenue from existing pipelines is projected to be around 9 billion RMB, with new pipeline sales expected to contribute approximately 6 billion RMB [2] - The company has successfully commercialized the drug Nefukang, which has rapidly gained market traction, demonstrating its commercial capabilities [7][10] Group 3: Research and Development - CloudTop New Horizon is advancing its self-developed mRNA platforms, including CAR-T and tumor vaccine platforms, with ongoing clinical trials [8][9] - The company plans to expand its R&D capabilities by introducing and incubating potential platforms, aiming to strengthen its core therapeutic areas [9][10] - The new reversible BTK inhibitor EVER001 has shown promising clinical data, indicating a steady global R&D progress [9] Group 4: Commercialization Strategy - The company is leveraging its integrated commercialization platform, which combines scientific and market insights, to enhance its operational efficiency and productivity [4][8] - The collaboration with Haisen Biopharmaceuticals exemplifies the company's ability to extend its commercialization capabilities to mature products [8] - The company aims to transition from a biotech firm to a comprehensive biopharmaceutical company with global competitiveness, reflecting a broader trend in the Chinese innovative drug industry [8][10]

12月11日，云顶新耀(HKEX1952.HK)宣布，其全资附属公司云顶新耀医药科技与海森生物签署两项战 略合作协议：商业化服务协议以及授权许可协议。两项协议将在财务与战略上形成显著协同效应，提升 现有商业化平台的运营效率，加快云顶新耀产品全生命周期、全渠道覆盖的商业化能力建设，同时为公 司在心血管疾病领域打造具有吸引力的业务版图。 对于两项协议的价值，云顶新耀表示，将在财务与战略上形成显著协同效应，提升现有商业化平台的运 营效率，加快产品全生命周期、全渠道覆盖的商业化能力建设。通过此次合作，公司将巩固在中国的商 业化基础，提升市场份额，为心血管业务的长期增长注入核心动力。 根据商业化服务协议，云顶新耀医药科技将依托现有销售与市场体系，为海森生物旗下六款成熟产品提 供商业化服务，覆盖急重症、心血管和代谢三大治疗领域。云顶新耀医药科技将按相关产品季度净销售 总额的20%-55%收取服务费，预计2026-2028年海森生物拟支付的年度交易金额上限分别为5.6亿元、 6.16亿元和6.77亿元。 在业内人士看来，云顶新耀此次合作既体现出其商业化能力的应用延伸，既为海森生物的成熟产品提供 市场支持，也能借助自身渠道将 ...